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Abstract
Background—The public health objective for cerebral palsy (CP) in the United States is to 
reduce the percentage of children with CP who were born low birthweight (LBW, <2500 g) by 
10% between 2006 and 2020. This study reports the prevalence of CP in a constant surveillance 
area for the years 2006, 2008, and 2010 and describes initial progress towards the CP public health 
objective.
Methods—Data on children with CP at age 8 years were ascertained by the Autism and 
Developmental Disabilities Monitoring (ADDM) Network, a population-based surveillance system 
that monitored CP in four areas of the United States.
Results—CP prevalence in 2010 was 2.9 per 1000 [95% confidence interval (CI) 2.6, 3.2], down 
from 3.5 (95% CI 3.2, 3.9) in the same surveillance area in 2006. Among CP cases with no 
documented postneonatal aetiology, 49.1% (95% CI 42.9, 55.2) were born LBW in 2010 
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compared with 54.3% (95% CI 48.4, 60.1) in 2006. In 2010, 28.1% (95% CI 22.9, 30.4) were born 
very low birthweight (VLBW, <1500 g) compared with 35.4% (95% CI 30.0, 41.2) in 2006. The 
relative risks for associations between CP and both LBW and VLBW also declined, though not 
significantly, during the study period.
Conclusions—Declines in the associations between CP and LBW categories may have 
contributed to declines during the study period in both the prevalence of CP and the percentage of 
children with CP who were born LBW or VLBW. Ongoing monitoring of these trends is 
warranted.
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The Healthy People 2020 (HP2020) public health objective for cerebral palsy (CP) in the 
United States is to reduce by 10%, between 2006 and 2020, the percentage of children with 
CP who were born low birthweight (LBW, <2500 g).1 In the baseline year of 2006, this 
percentage was estimated, based on Autism and Developmental Disabilities Monitoring 
(ADDM) Network data, to be 50.0 for all 8-year-old children with CP. This percentage was 
54.3 in 2006 among CP cases with no documented postneonatal cause of CP in four states 
that were monitored in 2006 and in two subsequent surveillance years, 2008 and 2010. 
Using 54.3% as the baseline for the percent born LBW among CP cases not attributed to a 
post-neonatal cause, and the objective of a 10% reduction in this percentage, we estimate 
that the target would be to reduce the percentage born LBW in this group to 48.9% by the 
year 2020.
The background for this public health objective is the experience of the last quarter of the 
20th century and first decade of the 21st century, when there was a gradual rise in the 
frequency of preterm birth and LBW among all livebirths in the United States and among 
infants surviving to 1 year.2,3 This trend, attributed to advances in perinatal medicine and 
neonatal intensive care,4 led to concerns that improvements in survival of very preterm and 
LBW infants would be accompanied by increases in the prevalence of CP in the population 
overall if the risk of CP remained constant within birthweight categories.5–7 Fortunately, 
beginning in the 1990s, following the introduction of antenatal corticosteroids and other 
interventions to improve outcomes of preterm birth, marked decreases in the risk of CP in 
cohorts born preterm or very low birthweight (<1500 g, VLBW) were observed.8–11 Given 
these trends, a reasonable public health goal might be to achieve measurable decreases at the 
population level in the risk of CP among infants born preterm or LBW. However, our ability 
to directly measure progress towards such a goal would require a population-based, 
longitudinal surveillance system, measuring developmental outcomes through early 
childhood in successive birth cohorts over time. No such system exists in the United States.
An alternative approach, possible with surveillance data from the ADDM Network, is to 
retrospectively monitor trends in the percentage of children with CP in the population who 
were born LBW. If ongoing improvements in the survival of LBW infants are accompanied 
by large enough reductions in the risk of CP associated with LBW, to counter the rising 
number of infants born LBW, we would expect to see reductions over time in the percentage 
Durkin et al. Page 2













of children with CP who were born LBW, making the HP2020 objective for CP a 
measurable goal.
The purposes of this article are to provide updated information on the prevalence of CP 
among 8-year-old children for year 2010 in the four ADDM Network surveillance sites, 
where CP prevalence has been monitored since 2006, and to assess initial progress towards 
the HP2020 public health objective for CP by describing the percentage of children with CP 
not attributable to postneonatal causes who were born LBW for each of three surveillance 
years, 2006, 2008, and 2010. In addition to LBW, results are presented for VLBW and 
stratified by sex, by race and ethnicity, and by two co-occurring conditions, epilepsy and 
autism spectrum disorder (ASD). Additional aims are to describe the associations between 
CP and both LBW and VLBW and to evaluate whether these associations declined during 
the 2006–10 surveillance years.
Methods
The ADDM Network monitored CP among 8-year-old children living in four areas in the 
United States, including central Alabama; metropolitan Atlanta, Georgia; metropolitan St. 
Louis, Missouri; and southeastern Wisconsin in 2006, 2008, and 2010. The prevalence of CP 
for the surveillance years 2006 and 2008 was published previously for a broader study area 
than the area under surveillance in 2010.12,13 In one site, the size of the surveillance area 
changed over time. To allow comparisons over time, this report is restricted to counties in 
the four states that were under surveillance in all 3 years, 2006, 2008, and 2010 (Table 1).
The methodology for CP surveillance was based on that developed by the CDC’s 
Metropolitan Atlanta Developmental Disabilities Surveillance Program, an ongoing, 
population-based, multisource surveillance programme that monitors the occurrence of 
developmental disabilities among 8-year-old children in metropolitan, Atlanta, and that has 
been described in detail previously.12–16 For surveillance purposes, we defined CP as a 
group of permanent disorders of movement and posture that are attributed to nonprogressive 
disturbances in the developing brain. CP is more than a motor impairment: it is a disorder 
often accompanied by disturbances of sensation, perception, cognition, communication, and 
behaviour; by epilepsy; and by secondary musculo-skeletal problems.17 This surveillance 
case definition includes cases with a documented postneonatal (>28 days after birth to age 8 
years) cause. For analyses monitoring trends in the percent LBW, we restricted the CP cases 
to those with no documented postneonatal aetiology, which included approximately 93% of 
the CP cases each year.
Case inclusion criteria were as follows: residence in one of the respective surveillance areas 
during years 2006, 2008, or 2010 at any time during the age of 8 years; and documentation 
of a CP diagnosis or physical findings consistent with CP in an evaluation by a qualified 
professional at or after 2 years of age. Children suspected of having CP were identified by 
screening comprehensive evaluations at multiple sources, including hospitals, clinics, 
diagnostic centres, health care providers, and state public health and rehabilitation agencies. 
In Georgia, potential cases also were identified through public school special education 
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programmes. Records containing one or more evaluations with a confirmed or suspected CP 
diagnosis or descriptions of physical findings consistent with CP were abstracted.
Demographic data, diagnostic summaries, descriptions of physical findings and motor 
functioning, and information about co-occurring disabilities were collected. Race and 
ethnicity of each child was determined from information in clinical or education records or 
from birth certificate information and classified as white non-Hispanic, black non-Hispanic, 
Hispanic, other, or undetermined. Data were combined into one composite record per child 
and subsequently reviewed by clinicians using a specified protocol to determine case status. 
Clinician reviewers included developmental paediatricians, a paediatric neurologist, physical 
therapists, and occupational therapists. In the absence of excludable conditions, such as 
progressive disorders and neuromuscular diseases, children were classified as confirmed CP 
cases based on diagnostic information and physical finding descriptions consistent with CP 
in the abstracted records.
Two methods for classifying gross motor function were incorporated into clinician review. 
When sufficient information on gross motor function at or after 4 years of age was 
abstracted, clinician reviewers used the Gross Motor Function Classification System 
(GMFCS)18 to assign a functional level. GMFCS is based on the gross motor skills needed 
for self-initiated movement, including sitting, transferring, and mobility. Due to reliance on 
the documented findings in the source files, we were unable to assign a GMFCS level for all 
cases.19
Motor function was also classified based on walking ability as ‘unaided walking’, ‘walking 
with aids’, or ‘unable to walk’.20 In determining walking ability, children classified as 
GMFCS Levels I or II were categorised as ‘walks independently’; Level III as ‘walks with 
handheld mobility device’; and Levels IV or V as ‘limited or no walking ability’. For 
children with insufficient information to GMFCS level, walking ability was independently 
assigned.21
Definitions of co-occurring developmental disabilities
Epilepsy—Children older than 1 month were identified as having epilepsy if evaluations by 
qualified professionals documented diagnoses of epilepsy or an epilepsy syndrome, or 
included descriptions of two or more unprovoked, nonfebrile seizures, >24 h apart.22
Autism spectrum disorder—Children were classified as having an autism spectrum 
disorder (ASD) if evaluation records documented behaviours consistent with the Diagnostic 
and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR)23 criteria for autistic 
disorder; pervasive developmental disorder, not otherwise specified; or Asperger disorder.
Data on birthweight
For children with CP whose place of birth was in the same state as their residence at age 8 
years (N = 916 or 76.3% of the cases) and for all births in the respective surveillance sites 
and birth years (1998, 2000, and 2002), information on birthweight, gestational age, sex, and 
race and ethnicity was obtained from birth certificates. For CP cases born in state, 
individual-level birth certificate information was linked to case data and then de-identified 
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before inclusion in the ADDM Network analytic files. For the birth cohort overall, we used 
de-identified birth records from the National Center for Health Statistics’ (NCHS) public use 
Natality and infant death data files.24 From these files, we constructed a birth cohort 
representing all infants surviving to 1 year born in one of the surveillance sites and birth 
years. The resulting birth cohort included 354 054 infants from the four sites and three birth 
years. As mentioned, birthweight <2500 g was classified as LBW, and birthweight <1500 g 
was classified as VLBW. We classified infants as preterm if gestational age at birth was <37 
weeks and as very preterm if gestational age was <32 weeks.
Data quality
Before independent review of abstracted records for case determination, initial inter-rater 
reliability was established among the reviewers to minimum standards of 90% agreement on 
case status. Ongoing quality control of both abstractors and clinician reviewers was 
conducted throughout the case identification and determination processes.25 Reliability was 
evaluated in a blinded, random 10% sample of abstracted records scored independently by 
two reviewers. Average percentage inter-rater agreement on final case status was 96% (linear 
weighted K = 0.91). Project staff performed no clinical examinations of children.
Data analysis
We calculated period prevalence using as the denominator the number of 8-year-old children 
residing in the surveillance areas according to the NCHS bridged-race 2010 decennial 
census population estimates.26
For CP cases with available birth certificate information and no documented postneonatal 
aetiology of CP, we calculated the percentages, with 95% CIs, of those born LBW and 
VLBW. Appendix 1 provides information on the percentages born LBW and VLBW among 
all CP cases with available birthweight information (i.e. including those with and without a 
documented postneonatal aetiology), and Appendix 2 provides a summary of the 
demographic and clinical characteristics of all CP cases in each surveillance year, stratified 
by the availability of birth certificate data.
We performed Cochran–Armitage chi-square tests for trend27 to evaluate the significance of 
trends over time in CP prevalence overall and in the frequency of LBW and VLBW among 
children with CP not attributed to postneonatal causes. Using the overall birth cohort as the 
comparison group, we calculated relative risks with 95% CIs28 to evaluate associations 
between CP risk and categories of LBW relative to birthweight ≥2500 g. The term relative 
risk is used here as a generic term for measure of association. For LBW, the relative risks 
were computed by dividing the number of birth cohort members born LBW who were 
identified as having CP with no documented postneonatal aetiology by the total number of 
cohort members born LBW, and then dividing this by the number of birth cohort members 
not born LBW who were identified as having CP with no documented postneonatal 
aetiology divided by the total number of birth cohort members who were not born LBW. The 
same approach was used to calculate relative risks for VLBW. These relative risks are 
similar to prevalence ratios, as the CP cases are ‘prevalent’ rather than ‘incident’ cases. 
However, the CP case group does not include cases from the birth cohort who moved out of 
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the surveillance area before the age of 8 years. For this reason, we were unable to compute 
prevalence and prevalence ratios in the birth cohort overall.
We tested the significance of differences in the relative risks from 2006 to 2010 using the 
approach described by Altman and Bland.29 P-values < 0.05 were considered statistically 
significant. We performed stratified analyses to evaluate the consistency of associations 
across subgroups and calculated population attributable risks to convey the proportion of CP 
cases in the population each year that may be attributed to LBW and VLBW, respectively.30 
We also evaluated the impact of adjusting for site effects on the associations between CP and 
both LBW and VLBW by computing adjusted odds ratios using logistic regression. Because 
the adjusted odds ratios were similar to the relative risks, we have not included them in this 
report. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, 
NC, USA) and SPSS version 22 (IBM Corp., Armonk, NY, USA).
Each participating site met applicable local institutional review board and privacy/
confidentiality requirements under 45 CFR 46.
Results
The prevalence of CP per 1000 8-year-old children in the combined surveillance area 
declined from 3.5 (95% CI 3.2, 3.9) in 2006 to 2.9 (95% CI 2.6, 3.2) in 2010 (Table 2, test 
for trend P = 0.036). Prevalence was lower in 2010 than in 2006 for both boys and girls, in 
each of the four surveillance sites, and among white non-Hispanic and Hispanic children, 
though the trends within most subgroups were not statistically significant. In contrast to 
other subgroups, no decline in the prevalence of CP was evident among black non-Hispanic 
children (Table 2).
In the birth cohort serving as the comparison group for the CP cases, the percent born LBW 
increased slightly, from 7.8 (95% CI 7.6, 7.9) in birth year 1998 to 8.1 (95% CI 8.0, 8.3) in 
2002, while the percentage born VLBW was constant during the study period at 1.3% (Table 
3).
In contrast, among children with CP not attributed to postneonatal causes and with available 
birthweight information, the percentage born LBW declined by 9.6% during the study 
period, from 54.3% (95% CI 48.4, 60.1) in 2006 to 49.1% (95% CI 42.9, 55.2) in 2010. This 
trend was not statistically significant (test for trend P = 0.213, Table 3). The percentage of 
these cases born VLBW declined by >20%, from 35.4% (95% CI 30.0, 41.2) in 2006 to 
28.1% (95% CI 22.9, 34.0) in 2010 (P = 0.066, Table 3). The direction of these trends was 
fairly consistent across demographic subgroups (Table 3). Analogous results are provided in 
Appendix 3 for the categories of preterm and very preterm birth.
Comparing CP cases not attributed to postneonatal causes to the birth cohort overall, and 
using births ≥2500 g as the reference group, the relative risks indicating associations 
between CP and both LBW and VLBW appeared to decline during the study period, from 
13.9 (95% CI 11.0, 17.4) in 2006 to 10.8 (95% CI 8.5, 13.7) in 2010 for LBW and from 39.1 
(95% CI 30.9, 49.5) to 28.6 (95% CI 22.0, 37.2) for VLBW (Table 4). The differences 
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between the relative risks in 2006 and 2010, however, were not significantly different from 
zero for either LBW (P = 0.136) or VLBW (P = 0.082).
The population attributable risks for LBW were 50.2% (95% CI 41.2, 56.1) in 2006 and 
44.3% (95% CI 37.9, 50.7) in 2010. For VLBW, they were 33.1% (95% CI 16.3, 38.7) in 
2006 and 26.4% (95% CI 21.5, 32.0) in 2010.
Comments
This is the first population-based study in the United States to show a significant decline in 
the population prevalence of CP. It also showed preliminary evidence, though not 
statistically significant, of declining trends in the association between CP and both LBW and 
VLBW. The findings are encouraging given concern raised in earlier decades that increases 
in the survival of infants at greatest risk of CP (i.e. those born preterm and VLBW) may 
have given rise to increases in the population prevalence of CP.5–7 This study was only able 
to monitor CP prevalence in a common surveillance area for the years 2006, 2008, and 2010. 
Although the results are encouraging, it is not possible to know from the data available 
whether the significant decline in CP prevalence observed during the study period is due to 
advances in health care for infants born VLBW. Nor is it possible to predict from the initial 
results reported here whether declines in CP prevalence and its association with LBW will 
continue after 2010.
Less hopeful were our findings of no decline in CP prevalence for black non-Hispanic 
children during the study period, and evidence that the racial disparity in CP prevalence 
appeared to increase over time. In 2010, the prevalence of CP was 68% higher in black 
children relative to white children (Table 2). These findings are difficult to reconcile with 
our observation that the contribution of LBW and VLBW to the risk of CP appeared to 
decline for both black and white children, and with previous research showing that the 
excess prevalence of CP among black children in the United States is largely explained by 
the excess frequency of LBW among black infants.31,32 Further research is needed to 
identify other risk factors contributing to the excess prevalence of CP among black children 
and to identify and monitor strategies to reduce the risk of CP and to reduce racial disparities 
in CP risk in the United States.
The results of this study suggest that initial progress was made by 2010 towards the HP2020 
objective of reducing by 10% between 2006 and 2020 the percentage of children with CP 
who were born LBW. By 2010, this percentage among CP cases with no documented 
postneonatal aetiology had declined by 9.6%. Even more impressive was the 20% decline 
during the study period in the percentage of CP cases born VLBW. Although encouraging, 
these trends are limited to three surveillance years and were not statistically significant due 
to the limited size of the population covered by the ADDM Network CP surveillance system. 
Nor are the results based on a probability sample selected to be representative of the nation. 
We reiterate that ongoing monitoring is necessary to evaluate future trends and progress 
towards the HP2020 CP objective. If improvements in neurodevelopmental outcomes of 
VLBW have occurred due to advances in perinatal and neonatal medicine in the 1990s and 
early 2000s, it is unclear that the pace of those advances will continue. Future trends in the 
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percentage of CP cases born LBW might also be affected by overall trends in the frequency 
of LBW and preterm birth among all livebirths. After decades of gradually increasing, the 
percentages of births in the United States that were LBW or preterm peaked in 2006 and 
have declined slightly over time since then.33
Additional limitations of this study are that birth-weight information was available only for 
the approximately 75% of CP cases who were born in the state in which they resided at age 
8 years and that the occurrence of CP could not be ascertained for an unknown number of 
birth cohort members no longer residing in the surveillance area at that age. Because of these 
limitations, we reported the prevalence of CP in the population of 8-year-olds using census 
counts for the denominator, rather than the prevalence or cumulative incidence in the birth 
cohort. For evaluating birth-weight trends, it was necessary to rely on the birth cohort rather 
than census counts and the subset of CP cases with available birth certificate information. A 
limitation of this approach is that the relative risks could be affected by selection bias if the 
birthweight distributions of CP cases residing in the surveillance area at age 8 were different 
from those of an unknown number of CP cases from the birth cohort who could not be 
identified by the surveillance system, because they were no longer living in the surveillance 
area at age 8 years. However, we have no evidence that the birthweight distribution of CP 
cases from the birth cohort who could not be ascertained by the surveillance system because 
they did not reside in the surveillance area at age 8 differed from the distribution of CP cases 
from the birth cohort who were represented in the surveillance system. Moreover, even if 
these distributions did differ, we have no reason to think that the differences would have 
changed during the surveillance period to bias the relative risks or trends in the percentage of 
CP cases that were born LBW.
Another limitation of this study is that detailed information on prenatal, perinatal, and 
neonatal care was not available for the case group or cohort, precluding our ability to 
examine potential impacts at the population level of specific health care interventions that 
have been shown to improve neurodevelopmental outcomes of preterm birth and VLBW. 
Our observation that the frequency of LBW increased and the frequency of VLBW did not 
change over the study period in the overall cohort, while the relative risk for CP and both 
LBW and VLBW declined, though not significantly, is consistent with the possibility that 
advances in the perinatal and neonatal care of preterm infants might have contributed to 
declines in the risk of CP associated with LBW and the prevalence of CP in the population. 
Further research is needed to confirm this possibility and monitor future progress.
This study has a number of implications for public health monitoring related to CP. One is 
that to establish whether progress has been made towards the HP2020 objective of reducing 
by 10% the percentage of CP cases born at LBW, it is necessary to monitor this percentage 
in a population large enough to be able to find a 10% reduction to be statistically significant. 
Based on our baseline of 54.3%, and the CP prevalence estimates and percent with available 
birthweight information estimated from this study, it would be necessary to perform ongoing 
surveillance of CP in a population of at least 512 000 8-year-olds in order to have 80% 
power to detect a 10% reduction as statistically significantly different from no change. For 
the study year 2010, the size of the ADDM CP Network surveillance population was limited 
to 131 352, and the power to detect a 10% reduction in the percentage of CP cases born 
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LBW in this population was only 28%. With the sample size available, the minimum 
reduction in the HP2020 CP indicator that would be detectable given a power of 80% would 
be about 20%. If the initial trend from 2006 to 2010 were to continue beyond 2010, >a 20% 
reduction in the indicator could be achieved by the year 2020. Given the fact that VLBW is a 
much stronger risk factor for CP than the broader category of LBW, future public health 
objectives for CP would benefit from including reductions in the percentage of children with 
CP who were born VLBW.
In summary, our preliminary findings of progress towards the HP2020 objective for CP and 
the significant decline during the study period in the population prevalence of CP are 
encouraging trends. Future monitoring of progress will require ongoing surveillance in 
relatively large surveillance areas that are consistent over time. These results also point to 
the need for further research to investigate the long-term developmental impacts at the 
population level of improvements in perinatal and neonatal care and to identify strategies to 
eliminate racial disparities in the United States in the risk of both LBW and CP.
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Appendix 1
Frequency of birthweight categories among all cerebral palsy (CP) cases (including those 
with documented post-neonatal aetiology) at age 8 years, by surveillance year, by race and 
ethnicity, sex, co-occurring epilepsy, and co-occurring autism spectrum disorder (ASD).
All CP cases with available birth certificate 
data, including those with documented 
postneonatal aetiology, age 8 years
Surveillance year 
2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 
2010 (birth year 
2002)
Total number of CP cases 316 314 286
 % LBW 51.6 47.1 47.2
 % VLBW 33.5 30.9 26.6
Number of white non-Hispanic cases 175 156 120
 % LBW 43.4 40.4 40.8
 % VLBW 20.6 21.8 19.2
Number of black non-Hispanic cases 114 121 126
 % LBW 62.3 54.5 54.0
 % VLBW 50.9 40.5 34.9
Number of Hispanic CP cases 13 26 26
 % LBW 76.9 42.3 42.3
 % VLBW 61.5 26.9 19.2
Number of boys 173 194 158
 % LBW (95% CI) 49.1 48.5 44.3
 % VLBW (95% CI) 32.4 30.4 27.2
Number of girls 143 120 128
 % LBW (95% CI) 54.5 45.0 50.8
 % VLBW (95% CI) 35.0 30.4 27.2
Number with co-occurring epilepsy 111 127 125
 % LBW (95% CI) 43.2 45.7 44.0
 % VLBW (95% CI) 26.1 26.0 25.6
Number with no co-occurring epilepsy 205 187 161
 % LBW (95% CI) 56.1 48.1 49.7
 % VLBW (95% CI) 37.6 33.8 27.3
Number with co-occurring ASD 20 21 23
 % LBW (95% CI) 70.0 42.9 56.5
 % VLBW (95% CI) 30.0 28.6 34.8
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All CP cases with available birth certificate 
data, including those with documented 
postneonatal aetiology, age 8 years
Surveillance year 
2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 
2010 (birth year 
2002)
Number with no co-occurring ASD 296 293 263
 % LBW (95% CI) 50.3 47.4 46.4
 % VLBW (95% CI) 33.8 31.1 25.9
CI, confidence interval; LBW, low birthweight (<2500 g); VLBW, very low birthweight (<1500 g).
Appendix 2
Frequency and characteristics of cerebral palsy (CP) cases (aged 8 years) by availability of 
birth certificate data, by surveillance year (2006, 2008, and 2010)a
Surveillance year 2006 (birth 
year 1998)
Surveillance year 2008 (birth 
year 2000)









































































Male sex 54.7 60.7 56.3 61.8 56.2 60.5 55.2 53.9 54.9
Race/ethnicity
 White, non-Hispanic 55.4 45.8 53.0 49.7 34.8 49.7 42.0 38.2 41.1
 Black, non-Hispanic 36.1 26.2 33.6 38.5 34.8 38.5 44.1 27.0 40.0
 Hispanic 4.1 12.1 6.1 8.3 10.1 8.7 9.1 11.2 9.6
 Other 4.1 9.7 5.4 3.5 3.4 3.5 4.5 11.2 6.2
 Unknown 0 7.5 1.9 0 16.9 3.7 0.3 12.4 3.2
CP subtype
 Spastic 80.0 82.2 81.3 76.4 73.0 75.7 82.9 83.1 82.9
 Hypotonic 4.4 5.6 4.7 5.3 6.5 5.5 6.3 1.1 5.1
 Ataxic/dyskinetic 0.9 0.9 0.9 2.5 5.6 3.2 1.0 3.4 1.6
 Mixed spastic 6.6 5.6 6.4 9.2 7.9 8.9 4.2 5.6 4.5
 Other/unspecified 7.0 5.6 6.6 6.1 6.7 6.2 5.6 6.7 5.9
Extent of limb involvement
 Quadriplegia/triplegia 21.8 17.8 21.8 16.2 20.2 17.1 25.5 16.9 23.5
 Diplegia 35.8 39.3 36.6 29.9 33.7 30.8 32.9 39.3 34.4
 Hemiplegia/monoplegia 23.1 24.3 23.4 30.3 19.1 27.8 24.5 27.0 25.1
 Unspecified 18.7 19.3 19.1 27.0 23.6 24.3 17.1 16.9 17.1
 Documented postneonatal aetiology 7.9 6.5 7.6 6.4 5.6 6.2 6.6 10.1 7.5
 GMFC available 74.4 76.6 74.9 73.2 83.1 75.4 73.8 75.3 74.1
GMFC among cases with available 
information
 I 35.1 47.9 38.2 40.8 39.1 40.5 45.0 56.7 47.8
 II 16.9 15.1 16.4 12.9 23.2 15.2 7.1 9.0 7.6
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Surveillance year 2006 (birth 
year 1998)
Surveillance year 2008 (birth 
year 2000)









































































 III 13.4 12.3 13.2 15.0 2.9 12.3 9.0 7.5 8.6
 IV 15.6 13.7 15.1 15.8 20.3 16.8 16.6 13.4 15.8
 V 19.0 11.0 17.1 15.4 14.5 15.2 22.3 13.4 20.1
 Walking ability available 74.9 77.3 75.4 72.6 77.2 74.7 81.1 86.5 82.4
Walking classification among cases 
with available information
 Walks independently 54.0 65.9 57.1 58.6 62.2 59.5 55.6 68.8 58.9
 With assistive device 11.5 9.8 11.0 12.8 1.4 10.0 8.2 6.5 7.8
 Limited or no walking 34.5 24.4 31.9 28.6 36.5 30.6 36.2 24.7 33.3
Co-occurring epilepsy 35.1 31.8 34.3 40.4 37.1 39.7 43.7 38.2 42.4
Co-occurring ASD 6.3 15.0 8.5 6.7 7.9 6.9 8.0 5.6 7.5
GMFC, Gross Motor Functional Classification; ASD, autism spectrum disorder.
a
Results for surveillance years 2006 and 2008 have been reported previously based on a larger surveillance area.11,12 The 
results here are restricted to a surveillance area composed of counties that were included in all three surveillance years.
Appendix 3
Frequency of preterm (<32 weeks’ gestational age) and very preterm (<32 weeks’ 
gestational age) birth among all livebirths surviving beyond 1 year and among cerebral palsy 
(CP) cases at age 8 years, by surveillance year, by race and ethnicity, sex, co-occurring 
epilepsy, and co-occurring autism spectrum disorder (ASD).
Surveillance year 
2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 





Total number of births surviving to 
age 1 year
125 166 130 884 128 722
Number with gestational age 
information at birth
125 025 130 803 128 676
 % Preterm (95% CI) 11.9 (11.7, 12.0) 11.9 (11.7, 12.0) 12.5 (12.3, 12.6) <0.001
 % Very preterm (95% CI) 1.8 (1.7, 1.9) 1.8 (1.8, 1.9) 1.8 (1.2, 1.4) 0.381
Total number of white, non-Hispanic 
births surviving to age 1 year (% of 
total white non-Hispanic births)
75 141 74 437 70 688
 % Preterm (95% CI) 9.9 (9.7, 10.1) 10.3 (10.0, 10.5) 10.8 (10.6, 11.1) <0.001
 % Very preterm (95% CI) 1.2 (1.1, 1.3) 1.3 (1.2, 1.3) 1.3 (1.2, 1.4) 0.161
Total number of black, non-Hispanic 
births surviving to age 1 year (% of 
total black non-Hispanic births)
37 587 38 898 37 005
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2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 





 % Preterm (95% CI) 16.6 (16.2, 16.9) 16.1 (15.7, 16.5) 17.1 (16.7, 17.5) 0.057
 % Very preterm (95% CI) 3.3 (3.1, 3.5) 3.2 (3.1, 3.4) 3.1 (2.9, 3.2) 0.075
Total number of Hispanic births 
surviving to age 1 year (% of total 
Hispanic births)
6156 9348 11 831
 % Preterm (95% CI) 8.5 (7.8, 9.2) 9.1 (8.5, 9.7) 9.4 (8.9, 10.0) 0.038
 % Very preterm (95% CI) 1.0 (0.8, 1.3) 0.9 (0.7, 1.1) 1.1 (0.9, 1.3) 0.367
CP cases with no documented 
postneonatal aetiology (age 8 years) 
with available birth certificate data
 Total number of CP cases 291 294 267
 Number with gestational age 
information at birth
290 294 267
  % Preterm (95% CI) 52.1 (46.2, 57.9) 52.0 (46.2, 57.9) 48.7 (42.6, 54.9) 0.213
  % Very preterm (95% CI) 35.9 (30.3, 41.7) 35.4(30.0, 41.2) 31.1 (25.7, 37.1) 0.241
 Number of white non-Hispanic 
cases
161 147 118
  % Preterm (95% CI) 44.7 (37.0, 52.7) 45.6 (37.4, 54.0) 43.2 (34.2, 52.7) 0.825
  % Very preterm (95% CI) 22.2 (17.9, 31.7) 27.9 (21.0, 36.0) 23.7 (16.6, 32.6) 0.989
 Number of black non-Hispanic 
cases
103 111 110
  % Preterm (95% CI) 61.2 (51.0, 70.5) 58.6 (48.8, 67.7) 55.5 (45.7, 64.8) 0.398
  % Very preterm (95% CI) 54.2 (42.4, 62.3) 44.1 (34.8, 53.9) 39.1 (30.1, 48.9) 0.052
 Number of Hispanic CP cases 13 25 25
  % Preterm (95% CI) 76.9 (46.0, 93.8) 52.0 (31.8, 71.7) 44.0 (25.0, 64.7) 0.068a
  % Very preterm (95% CI) 53.9 (26.1, 79.6) 28.0 (12.9, 49.6) 24.0 (10.2, 45.5)
 Number of boys 158 181 143
  % Preterm (95% CI) 50.6 (42.6, 58.6) 54.7 (47.2, 62.1) 49.0 (40.1, 57.4) 0.795
  % Very preterm (95% CI) 34.2 (27.0, 42.2) 35.4 (28.4, 42.9) 33.6 (26.0, 42.0) 0.919
 Number of girls 132 113 124
  % Preterm (95% CI) 53.8 (44.9, 62.4) 47.8 (38.4, 57.4) 48.4 (39.4, 57.5) 0.383
  % Very preterm (95% CI) 37.9 (29.7, 46.8) 35.4 (26.8, 45.0) 28.2 (20.7, 37.1) 0.105
 Number with co-occurring epilepsy 99 122 114
  % Preterm (95% CI) 43.4 (33.6, 53.8) 46.7 (37.7, 55.9) 46.5 (37.2, 56.0) 0.665
  % Very preterm (95% CI) 29.3 (20.8, 39.4) 24.6 (17.5, 33.4) 28.1 (20.3, 37.4) 0.869
 Number with no co-occurring 
epilepsy
191 172 153
  % Preterm (95% CI) 56.5 (49.2, 63.6) 55.8 (48.1, 63.3) 50.3 (42.8, 59.1) 0.263
  % Very preterm (95% CI) 39.3 (32.4, 46.6) 43.0 (35.6, 50.8) 33.3 (26.1, 41.5) 0.303
 Number with co-occurring ASD 20 20 23
  % Preterm (95% CI) 55.0 (32.1, 76.2) 50.0 (27.9, 72.2) 52.2 (31.2, 72.6) 0.862
  % Very preterm (95% CI) 30.0 (12.8, 54.3) 30.0 (12.8, 54.3) 34.8 (17.2, 57.2) 0.733
 Number with no co-occurring ASD 270 274 244
  % Preterm (95% CI) 51.9 (45.7, 57.9) 52.2 (46.1, 58.2) 48.4 (42.0, 54.8) 0.439
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2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 





  % Very preterm (95% CI) 36.3 (30.6, 42.4) 35.8 (30.2, 41.8) 30.7 (25.1, 37.0) 0.192
ASD, autism spectrum disorder; CI, confidence interval; CP, cerebral palsy.
a
P-value not calculated due to small expected cell sizes.
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Table 1
Population characteristics for 8-year-old children by site, Autism and Developmental Disabilities Monitoring 
Network, surveillance years 2006, 2008, and 2010a
Surveillance year
2006 n (%) 2008 n (%) 2010 n (%)
Total 8-year-old children 121 843 (100) 124 632 (100) 131 352 (100)
Male 62 062 (50.9) 63 786 (51.2) 66 604 (50.7)
Race and ethnicity
 White non-Hispanic 65 189 (53.5) 65 094 (52.2) 67 801 (51.6)
 Black non-Hispanic 40 053 (32.9) 40 119 (32.2) 40 420 (30.8)
 Hispanic 11 090 (9.1) 13 899 (11.2) 16 956 (12.9)
 Other 5511 (4.5) 5520 (4.4) 6175 (4.7)
Surveillance site
 Alabamab 21 101 (17.3) 21 473 (17.2) 21 833 (16.6)
 Georgiac 43 241 (35.5) 45 248 (36.3) 48 529 (37.0)
 Missourid 26 138 (21.5) 25 301 (20.3) 25 367 (19.3)
 Wisconsine 31 363 (25.7) 32 610 (26.2) 35 623 (27.1)
a
Data were obtained from the National Center on Health Statistics’ bridged-race census population estimates for each surveillance year. For 2006 
and 2008, they were from intercensal population estimates.
b
The Alabama site included nine counties in central Alabama.
c
The Georgia site included five counties of metropolitan Atlanta.
d
The Missouri site included five counties in metropolitan St. Louis.
e
The Wisconsin site included 10 counties in southeastern Wisconsin.
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Table 2
Prevalence per 1000 (95% CI) of cerebral palsy (CP) among 8-year-old children by site, Autism and 
Developmental Disabilities Monitoring Network, surveillance years 2006, 2008, and 2010a
Surveillance year
Test for trend P-
value
2006 (N = 423 CP cases) 
prevalence per 1000 (95% 
CI)
2008 (N = 403 CP cases) 
prevalence per 1000 (95% 
CI)
2010 (N = 375 CP cases) 
prevalence per 1000 (95% 
CI)
Overall 3.5 (3.2, 3.9) 3.2 (2.9, 3.5) 2.9 (2.6, 3.2) 0.036
Sex
 Male 3.8 (3.3, 4.3) 3.8 (3.4, 4.3) 3.1 (2.7, 3.5) 0.083
 Female 3.1 (2.7, 3.6) 2.6 (2.2, 3.0) 2.6 (2.2, 3.0) 0.236
Race and ethnicity
 White non-Hispanic 3.4 (3.0, 3.9) 2.9 (2.5, 3.3) 2.2 (1.9, 2.6) 0.002
 Black non-Hispanic 3.5 (3.0, 4.1) 3.8 (3.2, 4.5) 3.7 (3.2, 4.3) 0.536
 Hispanic 2.3 (1.6, 3.4) 2.5 (1.8, 3.5) 2.1 (1.5, 2.9) 0.191
Surveillance site
 Alabamab 3.0 (2.3, 3.8) 3.3 (2.6, 4.2) 2.4 (1.8, 3.2) 0.392
 Georgiac 4.1 (3.5, 4.7) 4.0 (3.5, 4.6) 3.4 (2.9, 4.0) 0.094
 Missourid 3.2 (2.6, 4.0) 2.5 (2.0, 3.2) 2.7 (2.1, 3.4) 0.311
 Wisconsine 3.1 (2.5, 3.8) 2.7 (2.2, 3.3) 2.5 (2.0, 3.0) 0.481
Documented postneonatal cause
 No 3.2 (2.9, 3.5) 3.0 (2.7, 3.3) 2.6 (2.3, 2.9) 0.046f
 Yes 0.3 (0.2, 0.4) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3)
CI, confidence interval.
a
The prevalence results for surveillance years 2006 and 2008 have been reported previously based on a larger surveillance area.11,12 The results 
here are restricted to a surveillance area composed of counties that were included in all three surveillance years.
b
The Alabama site included nine counties in central Alabama.
c
The Georgia site included five counties of metropolitan Atlanta.
d
The Missouri site included five counties in metropolitan St. Louis.
e
The Wisconsin site included 10 counties in southeastern Wisconsin.
f
P-value not calculated due to small expected cell sizes.
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Table 3
Frequency of birthweight categories among all livebirths surviving beyond 1 year, and among cerebral palsy 
(CP) cases at age 8 years, by surveillance year, by race and ethnicity, sex, co-occurring epilepsy, and co-
occurring autism spectrum disorder (ASD)
Surveillance year 
2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 





Total number of births surviving to age 1 year (% of 
total births)
125 166 130 884 128 722
 % LBW (95% CI) 7.8 (7.6, 7.9) 7.9 (7.8, 8.1) 8.1 (8.0, 8.3) 0.002
 % VLBW (95% CI) 1.3 (1.2, 1.4) 1.3 (1.3, 1.4) 1.3 (1.2, 1.4) 0.787
Total number of white, non-Hispanic births surviving 
to age 1 year (% of total white non-Hispanic births)
75 172 74 459 70 705
 % LBW (95% CI) 5.9 (5.7, 6.1) 6.2 (6.0, 6.4) 6.3 (6.1, 6.5) 0.003
 % VLBW (95% CI) 0.8 (0.7, 0.9) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 0.183
Total number of black, non-Hispanic births surviving 
to age 1 year (% of total black non-Hispanic births)
37 689 38 936 37 025
 % LBW (95% CI) 12.1 (11.8, 12.4) 12.0 (11.8, 12.5) 12.6 (12.3, 12.9) 0.049
 % VLBW (95% CI) 2.4 (2.3, 2.6) 2.4 (2.3, 2.6) 2.3 (2.2, 2.5) 0.379
Total number of Hispanic births surviving to age 1 
year (% of total Hispanic births)
8510 12 604 15 464
 % LBW (95% CI) 5.4 (4.9, 5.9) 5.7 (5.3, 6.1) 5.7 (5.3, 6.1) 0.088
 % VLBW (95% CI) 0.8 (0.6, 1.0) 0.8 (0.7, 1.0) 0.8 (0.7, 1.0) 0.701
CP cases with no documented postneonatal aetiology 
(age 8 years) with available birth certificate data
 Total number of CP cases 291 294 267
  % LBW (95% CI) 54.3 (48.4, 60.1) 50.0 (44.2, 55.9) 49.1 (42.9, 55.2) 0.213
  % VLBW (95% CI) 35.4 (30.0, 41.2) 32.7 (27.4, 38.4) 28.1 (22.9, 34.0) 0.066
 Number of white non-Hispanic cases 161 147 118
  % LBW (95% CI) 46.0 (38.2, 54.0) 42.9 (34.8, 51.3) 40.7 (31.0, 50.1) 0.373
  % VLBW (95% CI) 22.4 (16.3, 29.7) 23.1 (16.8, 30.9) 19.5 (13.0, 28.0) 0.598
 Number of black non-Hispanic cases 104 111 110
  % LBW (95% CI) 65.4 (55.3, 74.3) 58.6 (48.9, 67.7) 60.0 (50.2, 69.1) 0.427
  % VLBW (95% CI) 52.9 (42.9, 62.7) 43.2 (34.0, 53.0) 40.0 (30.9, 49.8) 0.060
 Number of Hispanic CP cases 13 25 25
  % LBW (95% CI) 76.9 (46.0, 93.8) 44.0 (25.0, 64.7) 40.0 (21.8, 61.1) 0.050a
  % VLBW (95% CI) 61.5 (32.3, 84.9) 28.0 (12.9, 49.6) 16.0 (5.3, 36.9)
 Number of boys 158 181 143
  % LBW (95% CI) 51.9 (43.9, 59.9) 51.4 (43.9, 58.8) 53.1 (38.5, 55.4) 0.389
  % VLBW (95% CI) 34.2 (27.0, 42.2) 32.0 (25.4, 39.4) 29.4 (22.2, 37.7) 0.373
 Number of girls 133 113 124
  % LBW (95% CI) 57.1 (48.3, 65.6) 47.8 (38.4, 57.4) 51.6 (42.5, 60.6) 0.364
  % VLBW (95% CI) 36.8 (28.8, 45.7) 33.6 (25.2, 43.2) 26.6 (19.3, 35.4) 0.082
 Number with co-occurring epilepsy 100 122 114
  % LBW (95% CI) 47.0 (37.0, 57.2) 47.5 (38.5, 56.7) 46.5 (37.2, 56.0) 0.936
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Surveillance year 
2006 (birth year 
1998)
Surveillance year 
2008 (birth year 
2000)
Surveillance year 





  % VLBW (95% CI) 29.0 (20.6, 39.1) 27.0 (19.6, 36.0) 27.2 (19.5, 36.5) 0.775
 Number with no co-occurring epilepsy 191 172 153
  % LBW (95% CI) 58.1 (50.8, 65.1) 51.7 (44.3, 59.1) 51.0 (42.8, 59.1) 0.174
  % VLBW (95% CI) 38.7 (31.9, 46.1) 36.6 (29.5, 44.4) 28.8 (21.9, 36.7) 0.059
 Number with co-occurring ASD 20 20 23
  % LBW (95% CI) 70.0 (45.7, 87.2) 45.0 (23.8, 68.0) 56.5 (34.9, 76.1) 0.408
  % VLBW (95% CI) 30.0 (12.8, 54.3) 30.0 (12.8, 54.3) 34.8 (17.2, 57.2) 0.733
 Number with no co-occurring ASD 271 274 244
  % LBW (95% CI) 53.1 (47.0, 59.2) 50.4 (44.3, 56.4) 48.4 (42.0, 54.8) 0.278
  % VLBW (95% CI) 35.8 (30.1, 42.0) 32.8 (27.4, 38.8) 27.5 (22.1, 33.6) 0.044
CI, confidence interval; LBW, low birthweight (<2500 g); VLBW, very low birthweight (<1500 g).
a
P-value not calculated due to small expected cell sizes.
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Table 4
Relative risks (95% CI) for CPa by low birthweight categories (reference category = birthweight ≥2500 g) by 
surveillance year, overall and by race/ethnicity
Surveillance year 2006 (birth year 
1998) Relative risk (95% CI)
Surveillance year 2008 (birth year 
2000) Relative risk (95% CI)
Surveillance year 2010 (birth year 
2002) Relative risk (95% CI)
Overall
 ≥2500 g 1.0 (reference) 1.0 (reference) 1.0 (reference)
 LBWb 13.9 (11.0, 17.4) 11.5 (9.2, 14.4) 10.8 (8.5, 13.7)
 VLBWc 39.1 (30.9, 49.5) 34.2 (26.9, 43.4) 28.6 (22.0, 37.2)
Boys
 ≥2500 g 1.0 (reference) 1.0 (reference) 1.0 (reference)
 LBW 13.9 (10.2, 19.0) 13.3 (9.9, 17.7) 11.0 (7.9, 15.2)
 VLBW 39.5 (28.7, 54.5) 33.4 (24.6, 45.3) 32.7 (23.0, 46.6)
Girls
 ≥2500 g 1.0 (reference) 1.0 (reference) 1.0 (reference)
 LBW 14.1 (10.0, 19.9) 10.0 (6.7, 14.0) 10.8 (7.6, 15.3)
 VLBW 39.1 (27.7, 55.4) 35.6 (24.2, 52.3) 24.8 (16.8, 36.8)
White non-Hispanic
 ≥2500 g 1.0 (reference) 1.0 (reference) 1.0 (reference)
 LBW 13.3 (9.8, 18.1) 11.2 (8.1, 15.5) 10.1 (7.0, 14.6)
 VLBW 32.1 (22.3, 46.1) 31.0 (21.3, 45.1) 25.5 (16.3, 40.0)
Black non-Hispanic
 ≥2500 g 1.0 (reference) 1.0 (reference) 1.0 (reference)
 LBW 13.4 (9.0, 20.2) 10.2 (7.0, 14.9) 10.3 (7.0, 15.0)
 VLBW 43.3 (29.7, 63.4) 29.9 (20.7, 43.3) 27.1 (18.6, 39.5)
Hispanic
 ≥2500 g 1.0 (reference) 1.0 (reference) 1.0 (reference)
 LBW 59.6 (16.5, 215.5) 13.5 (6.2, 29.6) 10.8 (4.9, 24.0)
 VLBW 188.4 (63.8, 556.6) 54.1 (23.4, 125.2) 24.5 (8.5, 69.6)
CI, confidence interval; LBW, low birthweight (<2500 g); VLBW, very low birthweight (<1500 g).
a
CP cases restricted to those not attributed to a postneonatal cause.
b
P-value = 0.136 for the difference between the relative risk in 2006 and 2010.
c
P-value = 0.082 for the difference between the relative risk in 2006 and 2010.
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